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cell lines are typically non-engineered cells or engineered clones implying a considerable risk for 23 artefacts because of clonal variation. Genome engineering can also transform BioID, a proximity 24 labelling method that relies on fusing a bait protein to a promiscuous biotin ligase, BirA*, resulting in 25 the tagging of vicinal proteins. We here propose an innovative design to enable BioID for endogenous 26 proteins wherein we introduce a T2A-BirA* module at the C-terminus of endogenous p53 by genome 27 engineering, leading to bi-cistronic expression of both p53 and BirA* under control of the endogenous 28 promoter. By targeting a Cas9-cytidine deaminase base editor to the T2A auto-cleavage site, we can 29 efficiently derive an isogenic population expressing a functional p53-BirA* fusion protein. Using 30 quantitative proteomics we show significant benefits over classical ectopic expression of p53-BirA*, 31 and we provide a first well-controlled view on the proximal proteins of endogenous p53 in colon 32 carcinoma cells. This novel application for base editors expands the CRISPR/Cas9 toolbox and can be 33 Elucidating the composition and function of protein complexes is crucial for advancing our 51 understanding of key cellular processes, both in health as well as disease [1] . Fuelled by an ever-52 growing arsenal of so-called interactomics technologies [2] , vast amounts of data are now available 53 for further exploration [3, 4] . With expanding lists of interactors for every protein challenged, there is 54 a growing consensus in the field that many reported interactions are highly contextual or spatially 55 restricted [5] . In addition, it became apparent that approaches in which a bait protein is overexpressed 56 lack the subtlety that is needed to further dissect protein-protein interactions and assess physiological 57 functions of individual interactions [6] . Indeed, protein overexpression can have a detrimental effect 58 on protein localization and folding, and distort downstream signalling [5, 7] . Protein overexpression 59 also tends to mask complex feedback control mechanisms affecting a protein at physiological levels 60 and generally increases the overall stress status of a cell [8, 9] . Several efforts have been made to 61 avoid bait protein overexpression, with the use of primary antibodies to pull-down endogenous 62 protein complexes as prime example [10, 11] . In reality, the specificity and the sensitivity of antibodies 63 are often inadequate for studying endogenous protein complexes in a reliable manner and can 64 therefore lead to problems with reproducibility [12] . Despite improved methodologies it remains 65 challenging to generate specific antibodies with favourable affinities for each protein [13, 14] 66 especially when one wants to specifically study mutant proteins bearing amino acid substitutions or 67 truncated proteins originating from, for instance, alternative translation start sites (i.e. proteoforms 68 [15] ). For such situations, Flp-In TM cell lines allowing tunable expression provide a valuable alternative 69 [16] . However, this requires thoughtful and precise fine-tuning of expression levels to mimic as closely 70 as possible physiological protein levels [17] . Artificial chromosomes have also been used to express 71 transgenes at physiological levels [18] . 72 A technology that is gaining popularity to map protein interactomes is BioID. This method relies on a 73 promiscuous biotin ligase (BirA*) fused to a bait protein of interest [19] . BirA* is a mutagenized E. coli 74 biotin ligase (carrying the R118G mutation) that no longer displays substrate specificity. Upon 75 expressing a bait-BirA* fusion protein, proximity-dependent biotinylation occurs of proteins that are 76 near-neighbours of this bait protein in the cell. As endogenous biotinylation is a rare and highly specific 77 modification in mammalian cells [20, 21] , biotinylated prey proteins are easily discriminated after 78 purification by streptavidin matrices and mass spectrometry (MS) analysis. Moreover, the need for 79 lysis is removed since the labelling of prey proteins occurs in intact cells before the homogenization 80 step. Since its initial publication in 2012, BioID has been used to study proximal and interacting 81 proteins (i.e. the proxisome) of bait proteins in several organisms and cell types producing datasets 82 complementary to affinity purification -MS (AP-MS) approaches [22] . In bait overexpression 83 experiments, as controls, BirA* is often expressed alone or fused to irrelevant baits (e.g. eDHFR, eGFP), 84 although cellular localizations and expression levels might differ between BirA*-fusion proteins and 85
BirA* alone, which therefore confound results [19] . 86
Bi-cistronic expression systems can provide a way to ensure similar expression levels for a bait protein 87 In this report, we use a novel knock-in strategy to enable BioID experiments for endogenous p53 in 117 HCT116 colon carcinoma cells as classic overexpression experiments in this cell model gave suboptimal 118 results. In our knock in strategy, a control cell line was first generated by introduction of a T2A-BirA* 119 cassette at the C-terminus of endogenous p53 using CRISPR/Cas9 genome engineering. These cells 120 express the BirA* protein at equal levels to p53 and thus provide a good system to assess biotinylation 121 background. Targeted inactivation of the T2A peptide sequence by a Cas9 cytidine deaminase fusion 122 (BE3) results in the generation of a cell line that expresses a functional p53-BirA* fusion protein from 123 the endogenous promoter allowing proximal protein mapping for endogenous p53. This reduces 124 genome engineering efforts considerably and eliminates artefacts due to clonal variation when a 125 selection step is added in the protocol. Furthermore, the concept of auto-cleavage switching in fusion 126 proteins can find applications in synthetic biology. 127
The BioID biotin ligase BirA* was transferred from the pcDNA3.1 mycBioID vector (Addgene #35700) 140 by PCR to generate the pAav-TP53-T2A-BirA* targeting construct (available via Addgene, #115652). 141
All primers used in this manuscript can be found in table S1. Homology regions were generated by PCR 142 on genomic HCT116 DNA as described before [40, 41] . The pMet7-FLAG-PQS1-TP53-T2A-BirA*-Myc 143 construct was generated by standard restriction enzyme cloning procedures using the FLAG-PQS1-p53 144 expression vector published earlier [40] . This construct was further mutagenized by PCR to obtain a 145 construct bearing an inactivated T2A sequence for a BioID transient transfection experiment. A 146 puromycin selection cassette was incorporated in the BE3 (Addgene, plasmid #73021) vector for 147 endogenous mutagenesis purposes (BE3puro) using a linear dsDNA fragment (IDT DNA Technologies, 148 gBlock). gRNA sequences incorporated in a U6-driven expression cassette were ordered as gBlocks 149 (Table S2 ) prior to blunt-ended ligation in a pCR-Blunt vector (Thermo Fisher Scientific, K2750). 150 CRISPR/Cas9 genome engineering 151 HCT116 TP53 +/T2A-BirA* cells were generated using a combination of CRISPR/Cas9 and recombinant 152 Adeno-associated virus (rAAV)-mediated template delivery as described before [40, 41] . Briefly, a 153 TP53 C-terminal targeted gRNA (5' ACGCACACCUAUUGCAAGCA 3') was cloned in a Cas9 expression 154 construct (Addgene #48139) as described by Ran et al. [42] . Cells were seeded in a 24-well plate 24 h 155 before transfection with the Cas9 plasmid using FugeneHD (Promega, E2311). 48 h after transfection, 156 cells were infected with targeting construct packaged in rAAV. Neomycin selection (Gibco, 11811031) 157 was performed for two weeks starting 24 h after infection. Afterwards, cells were manually diluted 158 and seeded as single cells in 96-wells for further clonal expansion until on average, clones reached 159 70% confluence at which point they were split into a lysis plate and culture plate. Screening of clonal 160 populations in the lysis plate was based on junction PCR screening using GoTaq G2 Hot Start 161 polymerase (Promega, M7405). Input lysates for PCR were obtained using DirectPCR lysis reagent 162 (Viagenbiotech, 301C). Positive clones were seeded at 10 3 cells per 96-well 24 h prior to treatment 163 with 2.5 µM TAT-Cre (Excellgen, EG1001). 24 h after treatment, the medium was aspirated and 164 replaced with fresh growth medium. Four days after TAT-Cre treatment, cells were subjected to a 165 second round of single cell seeding and PCR screening. Clones showing aberrant growth rates or 166 morphology were omitted for further characterization. PCR-positive clones were subjected to 167
Western blot using 1/1000 diluted anti-p53 antibody (Calbiochem, OP43T) and near-infrared 168 fluorescent secondary antibodies (LI-COR). Additionally, Southern blot analysis was performed to 169 verify single genomic integration of the floxed neomycin resistance cassette. [α-32 P] Southern blot 170 probe was generated as described before.
[41] For every retained clone, engineered loci were verified 171 using Sanger sequencing as described earlier. Primers used for screening, sequencing and generation 172 of the Southern blot probe can be found in table S1. 173 T2A mutagenesis 174 7.2x10 5 HEK293T cells were seeded in 6-well plates the day prior to transfection. A total amount of 175 800 ng DNA was mixed with 4 µl polyethylenime (PEI) for every transfection condition and incubated 176 for 10 min at room temperature. Meanwhile cells were placed on 1.5 ml DMEM medium 177 supplemented with 2% FCS. 6 h after addition of the transfection mix, the medium was removed and 178 replaced by DMEM with additives after washing once with Phosphate Buffered Saline (PBS) (Gibco, 179 14190094). 72 h post transfection cells were washed with PBS before detachment using a cell scraper 180 (Greiner, 541070) and lysis in 2X SDS-PAGE XT sample buffer (Bio-Rad, 1610791) and XT reducing agent 181 (Bio-Rad, 1610792) by heating for 10 min at 95°C. Afterwards, 100 µl MilliQ water was added to dilute 182 samples prior loading on a QIAshredder homogenizer spin-column (Qiagen, 79656) and running them 183 on a Criterion XT 4-12% BisTris gel (Bio-Rad, 3450123). After blotting, the PVDF membrane was 184 incubated with anti-FLAG (Sigma, F1804) and anti-Myc (in-house produced) primary antibodies and 185 detected with LI-COR near-infrared fluorescent secondary antibodies. For endogenous mutagenesis, 186
BE3puro vector and gRNA plasmids were transfected using FugeneHD in HCT116 TP53 +/T2A-BirA* cells. 24 187 h after transfection, 2 µg/ml puromycin was added to the growth medium for 48 h to enrich for BE3puro 188 transfected cells prior to expansion for proteomics experiments. 189
Illumina targeted sequencing 190
For targeted sequencing, subconfluent 25 cm 2 bottles containing HCT116 TP53 +/T2A-BirA* cells after 191
BE3puro treatment and subsequent enrichment were pelleted by centrifugation at 500 g for 5 min and 192 washed once with PBS. To each pellet, 500 µl lysis buffer [20 mM Tris-HCl pH 7.5, 5 mM EDTA, 150 193 mM NaCl, 400 U Proteinase K (Sigma, P4850), 0.2% SDS] was added and incubated for 16 h at 37°C. 194 Afterwards, genomic DNA was obtained by phenol-chloroform extraction and ethanol precipitation. 195
Next, the T2A locus was amplified and provided with Nextera overhangs by PCR using Herculase 196 polymerase (Agilent, 600675). Sequencing was performed using the MiSeq Nano v2 kit (Illumina, 197 MS1022002) by the VIB Nucleomics core facility (http://www.nucleomics.be/). FASTQ files were 198 uploaded to CRISPRESSO [43] to analyse results. The CRISPRESSO allele frequency output file (Table  199 S3) was used as input to generate the sequence logo using the online tool WebLogo [44] . 200
Nuclear and cytoplasmic extraction 201
For every cell line, cells were cultured in McCoys medium supplemented with a final concentration of 202 10% dialyzed FBS as described above. 1 mM doxorubicin (Sigma, D1515) and 50 µM biotin (Sigma, 203 B4639) was added to the growth medium 24 h prior to the start of the experiment at which 7x10 6 cells 204 were pelleted by centrifugation at 500 g for 5 min. After washing once with ice-cold PBS and 205 centrifugation at 500 g for 5 min, the supernatant was aspirated from the cell pellet. Extraction was 206 done using the NE-PER kit (Thermo Fisher Scientific, 78833) according to the instructions provided by 207 the manufacturer. In brief, 500 µl ice-cold CER 1 buffer was added to every cell pellet before 208 resuspension by vortexing. After 10 min incubation on ice, 27.5 µl ice-cold CER 2 buffer was added to 209 the mix and samples were centrifuged at 16000 g on 4°C for 5 min. Supernatant resulting from this 210 centrifugation step was stored as cytoplasmic extract. The pellet fraction was resolved in 250 µl ice-211 cold NER and vortexed vigorously every 10 min for 15 s during an incubation period on ice for a total 212 of 40 min. Afterwards, nuclear extract was obtained by centrifugation at 16000 g for 10 min at 4°C and 213 the supernatant containing this nuclear extract was transferred to a new tube. 214
In parallel, 10 6 cells were washed once with PBS prior to resuspension in 150 µl ice-cold RIPA lysis 215 buffer [50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% NP-40, 1 mM EDTA, 1 mM EGTA, 0.1% SDS, 0.5% 216 sodium deoxycholate (DOC) and complete protease inhibitor cocktail (Roche, 11873580001)]. 217
Following 10 min incubation on ice, lysates were centrifuged at 16000 g for 15 min at 4°C and the 218 supernatant was transferred to a new tube (= total cell lysate sample). For every fraction, the protein 219 concentrations as determined by a Bradford assay and 40 µg was loaded on ExpressPlus SDS-PAGE 220 (GenScript, M42015) and afterwards blotted on a PVDF membrane. α-tubulin was used as cytoplasmic 221 marker (Sigma, T5168). 222
BioID affinity purification 223
For every sample three 145 cm 2 culture dishes (Nunc) were seeded with 4.5x10 6 HCT116 TP53 +/T2A-BirA* 224 cells cultured on McCoy's 5A modified medium supplemented with dialyzed FBS. 24 h after seeding 1 225 µM doxorubicin was added. To every culture dish biotin was added to a final concentration of 50 µM 226 at the start of the treatment. 24 h after treatment the growth medium was replenished to deprive 227 free biotin from the culture. 3 h later, the growth medium was aspirated and cells were washed once 228 with cold PBS before detachment in PBS using a cell scraper. After pelleting cells by centrifugation for 229 5 min at 500 g on 4°C, a second PBS washing step occurred prior to cell lysis in a 15 ml tube. 2 ml of 230 ice-cold RIPA lysis buffer containing 250 U of benzonase (Sigma, E1014) was added to each pellet. Lysis 231 was obtained by incubation with agitation for 1 h on 4°C prior to sonication (30% amplitude, 5 We set out to explore the so-called 'proxisome' of p53 in well-known and well-characterized colon 309 carcinoma HCT116 cells. The model system has been used extensively for the study of p53 function, 310 in part because of the availability of many knock out cell lines [53] . We were faced with the lack of an 311 inducible HCT116 cell line and we therefore decided to first explore an experiment with forced 312 expression of a p53-BirA* construct. We transiently transfected HCT116 cells with a fusion construct 313 that contains a C-terminal BirA* module cloned in frame through an inactivated T2A peptide that 314 served as a long linker (p53-MUTT2A-BirA*). As control experiments we used either mock-transfected 315 cells or cells transfected with a bi-cistronic p53-T2A-BirA* construct ( Figure 1A and 1B ). This last 316 construct ensured equal levels of the free BirA* module in the control cells, providing a distinct 317 advantage over expression of a free unfused BirA* protein which often requires tuning to obtain equal 318 expression levels. We performed triplicate experiments to allow LFQ analysis using MaxQuant and 319 Perseus workflows. Using the mock control, an extensive list of significant proteins for p53-BirA* was 320 obtained by LFQ analysis ( Figure 1C ). Of these, 17.1% were known p53 interaction partners in BioGRID. 321 Some well-known interaction partners can be discerned in the list, but despite the comprehensive list, 322
some key interaction partners such as MDM2 are lacking. This extensive list can be expected because 323 the control conditions lack any BirA*. When assessing the T2A-BirA* control condition we found some 324 distinct differences, pointing to removal of contaminants by the presence of BirA* in this control. 325 However, the retrieved lists were still surprisingly long with 408 significant proteins ( Figure 1D ), of 326 which 20.3% were known BioGRID p53 interaction partners. This large number of hits is likely due to 327 the excessive levels of BirA*, resulting in much background biotinylation in both transient expression 328 approaches. Levels of the fusion protein are well beyond the endogenous levels in the cells (Figure  329   1B ). In addition, GO analysis on 'molecular function' showed very few links to p53 function, with 'p53 330 binding' only retrieved at position 38 and 88 for the mock and T2A-BirA* control respectively. GO 331 analysis for 'cellular component' showed strong enrichment of cytoplasmic and membrane proteins 332 (Table S4 and , we decided to explore the exciting 339 developments in the genome editing field to engineer the BirA* module in one allele of the TP53 gene 340 in HCT116 cells. We started by first creating a control T2A-BirA* cell line as we reasoned that the best 341 way to ensure similar levels in the control condition is to use a bi-cistronic approach (Figure 2A) . Similar 342 BirA* control expression levels are also maintained when p53 protein levels are changed due to stress 343 conditions on the cells (e.g. DNA damage). We used CRISPR/Cas9 to introduce a double stranded DNA 344 (dsDNA) break in the last coding exon of TP53 and provided a single strand DNA (ssDNA) repair 345 template containing a T2A-BirA* module and a floxed expression cassette flanked by two homology 346 regions. Generation of this control cell line was performed using a two-step engineering approach as 347 described earlier ([40], Figure S1 ). Clones bearing insertions were identified by PCR ( Figure S2 ). In the 348 second step, the floxed selection cassette is removed by CRE recombinase, again followed by PCR 349 screening of single cell clones ( Figure S3 ). Single integration for these clones was shown by Southern 350 blot ( Figure S4A may introduce artefacts in the data. To solve these issues, we sought to derive an isogenic population 362 from the control cell line wherein the T2A site would not be present. This can be obtained by another 363 CRISPR/Cas9 knock-in approach using a template with an alternative linker (e.g. an inactive T2A site). 364
However, the efficiencies currently obtained for knock-in are too low to allow such an approach and 365 would still require clonal selection (see higher). As an alternate way to achieve T2A inactivation, we 366 turned to a recently reported Cas9-cytidine deaminase base editor BE3 [27] . Targeted inactivation of 367 the 2A sequence would ensure restoration of bait-BirA* transgene expression ( Figure 2B ). 2A peptides 368 have conserved amino acid residues that are critical for peptidyl transferase inhibition that causes 369 ribosomal skipping ( Figure 2C) [55, 56] . Therefore, the targeted mutagenesis of one of these key 370 residues should enable efficient abrogation of 2A ribosomal skipping activity. To explore this, we 371 generated an expression vector that expresses a fusion construct of the tumor suppressor protein p53 372 linked to BirA* by a T2A sequence. Appropriate codon usage of the T2A sequence was verified to 373 ensure the presence of several target nucleotides for BE3 ( Figure 2C) . Varying amounts of a FLAG-374 TP53-T2A-BirA*-MYC expression construct were co-transfected with the BE3 construct and T2A-375 specific gRNA. Two different gRNAs were assessed for base editing activity (Table S2 ). Conversion of 376 the auto-cleavage site was clearly detectable by the presence of a high molecular weight band 377 corresponding to a p53-BioID fusion construct on Western blot analysis ( Figure 2D) . 378
T2A conversion after integration by genome engineering 379
A puromycin selection cassette was first cloned into the original BE3 vector allowing for efficient 380 enrichment of transfected cells. This ensures that non-transfected cells, and thus non-edited cells, are 381 efficiently removed in a short puromycin selection step. These non-edited cells would generate 382 additional noise to downstream LFQ proteomics analysis [45] . The gRNA directly targets the conserved 383 amino acid residues on the T2A sequence while leaving p53 and BirA* intact (inactivated T2A is 384 hereafter indicated as MUTT2A). When assessing p53 translation products before or after BE3 385 transfection, a clear signal for p53-MUTT2A-BirA* was observed in puromycin-resistant cells (Figure  386 3A), a result which was obtained for multiple clones. Notably, an additional band with an apparent 387 molecular weight corresponding to WT p53 was also present. This extra band can be explained by the 388 heterozygous knock-in of T2A-BirA*. In HCT116 TP53 +/T2A-BirA* the modified p53 allele has 22 extra 389 amino acids due to translation of the GSG linker and the T2A peptide. This band could still be observed 390 in the enriched cell population post-transfection, hinting at a portion of cells that did not undergo T2A 391 sequence conversion. This partial conversion can be attributed to the intrinsic activity of BE3 that is 392 below 100%. Furthermore, it is likely that not all editing will result in T2A inactivation as BE3 393 mutagenesis activity is centered around positions 4 -8 in the protospacer sequence [27], therefore 394 mutations might be introduced that have no impact on T2A activity or only attenuate its potency. To 395 quantify the mutagenesis rate we performed next-generation sequencing on the resulting cell 396 population showing a conversion rate over 40% ( Figure 3B ). In agreement with earlier reports on base 397 editing, CRISPRESSO analysis showed that the rate of indel formation in the resulting population was 398 negligible and the mutagenesis window was restricted to the predicted nucleotides ( Figure S5) . 399
Next to efficient T2A inactivation, proper localization of p53-MUTT2A-BirA* and BirA* is clearly crucial 400 for the effectiveness and reliability of the system. Ideally, both the bait and the biotinylation activity 401 of the engineered cell lines should follow the same subcellular distribution before and after BE3 402 treatment to provide relevant background protein signals. To evaluate this, we derived nuclear and 403 cytoplasmic fractions of the engineered cells upon p53 activation by doxorubicin. We could observe a 404 clear nuclear enrichment for p53 in both parental and engineered cells, indicative that proper p53 405 localization is not impaired by knock-in of T2A-BirA* or base editor treatment ( Figure 3C ). As expected, 406 only in the BE3 treated engineered cells a strong signal for p53-T2A-BirA* could be observed in the 407 nuclear fraction. Furthermore, assessment of the biotinylation pattern showed an intense laddering 408 pattern in engineered cells when compared to the parental HCT116 cells ( Figure 3C ). Both before and 409 after BE3 treatment, biotinylation was mainly detectable in the nuclear fraction, which indicates that 410 the engineered cells with cleaved BirA* (p53-T2A-BirA*) provide a good control condition. 411
Additionally, biotinylated WT p53 can be clearly observed in BE3 treated cells, hinting that fusion to 412 BirA* is not affecting the oligomerization properties of p53 ( Figure 3C ). 413
Conversion of inserted T2A-BirA* as a potent tool to study the p53 proxisome 414
We then performed endogenous BioID experiments using the engineered and converted HCT116 415 TP53 +/MUTT2A-BirA* cells. Experiments were done in triplicate to allow MaxQuant LFQ analysis [45] . Cells 416 were harvested and lysed after provoking a p53 response by doxorubicin. Puromycin-selected HCT116 417 TP53 +/T2A-BirA* cells transfected with BE3 in absence of T2A-directed gRNA served as control condition 418 ( Figure 4A ). Following a two-sided t-test (FDR: 0.05, s0: 0.1) we observed 186 potential p53 interactors 419 for the mutagenized cells ( Figure 4B and table S6 ), resulting in a high-quality proxisome dataset for 420 p53. String pathway analysis showed a highly interconnected network around p53 with complexes 421 involved in transcription and chromatin remodelling ( Figure S6 ). Among the most differential proteins 422 is p53 (p-value <0.00001), supporting that T2A is mutagenized in a way that abrogates ribosomal 423 skipping by the peptide. In the control condition treated with doxorubicin, p53 was detected at lower 424 levels, hinting at rare events whereby the T2A peptide did not cause interruption of translation in 425 accordance with the Western blot analysis ( Figure 3A) were detected, enabling a robust protein inference (Table S6 ). GO analysis showed highly specific 432 enrichment for p53-related 'cellular component' and 'molecular function' terms (Table S7 ). 'p53 433 binding' can be found at position 13 with a p-value of 1.21x10 -10 . These results support the concept 434 that BioID on the endogenous protein level can be exploited to further characterize dynamic p53 435 interactions in a physiologically relevant context. 436
To show the benefit of using a converted T2A design strategy, we also compared non-engineered WT 437 control cells (transfected with BE3 and selected on puromycin) to the p53-MUTT2A-BirA* cells as this 438 would mimic a simpler design strategy ( Figure S7A ). This analysis revealed 397 differential proteins 439 with a clear enrichment of RNA-binding proteins and chaperones ( Figure S7B ; Table S8 ) with 'p53 440 binding' found on position 17 with a p-value of 3.62x10 -8 . When compared to the T2A-BirA* control 441 condition, 232 proteins were exclusively significant for the analysis using transfected HCT116 WT cells 442 ( Figure S7C ). A part of this extended protein list is also found in the BioGRID database as interactors 443 of p53. Strikingly, when these additional p53 BioGRID hits were assessed for 'cellular component' 444 terms they were mainly assigned as cytoplasmic proteins (180 proteins; p-value 9.19x10 -14 ), and their 445 'molecular function' was linked to functions such as RNA-binding (51 proteins; p-value 4.83x10 -17 ), 446 ribosomal constituents (34 proteins; p-value 1.03x10 -17 ) and poly(A) RNA or mRNA binding (142 and 447 15 proteins; p-values 2.02x10 -67 and 1.14x10 -6 respectively; Table S8 ). While these RNA-binding 448 proteins and chaperones can be bona fide interaction partners for p53, they likely turn up with many 449 different bait proteins (or directly with BirA*). Consequently, proteins with functions related to RNA 450 are typically enriched in contaminant repositories for affinity purification -mass spectrometry 451 experiments [64] . 452
DISCUSSION

453
Since its initial emergence, BioID has been widely adopted by the proteomics community to detect 454 protein-protein interactions and vicinal proteins because of its distinct advantages over classic AP-MS 455 [22] . However, virtually all efforts rely on ectopic (over)expression of bait proteins fused to BioID [22] . 456
To our knowledge, there is currently only one report where BioID is performed at the endogenous 457 level [65] . The endogenous application of BioID solves two important issues in typical MS-based 458 interactomics approaches. Firstly, the need for lysis is obviated since prey labelling occurs in intact 459 cells before the homogenization step, and secondly, overexpression artefacts are removed by using 460 the endogenous bait protein. This last issue is supported by our experiments with ectopic expression 461 of p53-BirA* wherein we clearly show extensive lists of candidate proximal proteins pointing to the 462 presence of many contaminants. Coupling expression levels of both bait-BirA* and control BirA* might 463 be of particular relevance for proteins, such as p53, that have varying expression levels depending on 464 the cellular state. One longstanding question in the p53 field is how p53 is able to elicit different 465 responses to separate stimuli or stress conditions in a cell. We believe that future studies with BioID 466 at the endogenous level may reveal some of the subtle interaction changes or altered feedback loops 467 that are potentially overlooked in overexpression studies, thereby providing missing pieces to the p53 468 puzzle. Furthermore, the majority of p53 research has been based on overexpression experiments and 469 therefore PPI databases may be riddled with interactions that are spatially and physiologically not 470 possible in an intact cell. Although highly specific anti-p53 antibodies are commercially available for 471 conducting endogenous immunoprecipitation MS experiments, these will always have the drawback 472 that protein complexes need to be kept intact during purification. While crosslinking of protein 473 complexes may improve conservation during purification, crosslinking is prone to inter-experimental 474 variation in efficiency, suffers from ambiguous experimental data and can lead to problematic 475 identification of crosslinked peptides by search algorithms [66] . 476
We engineered a single cell line that can be used both as a control and an experimental cell line 477 without the need to go through an additional intermediary single cell stage. Our approach relies on 478 mutagenesis of a T2A sequence incorporated as a linker between a bait protein of interest and a 479 functional tag sequence, here BirA*. By mutagenizing the T2A site, ribosomal skipping is prevented 480 and a functional fusion construct is generated. We showed the concept of T2A mutagenesis on vectors 481 for overexpression and on a knock-in HCT116 TP53 +/T2A-BirA* cell line. In addition, we show correct 482 localization of the BirA* enzyme in the modified cells, both before and after T2A inactivation. Based 483 on these results, we believe that our approach is suitable for cytoplasmic and nuclear bait proteins. 484
The current system does not allow to target the released BirA* to restricted compartments (e.g. 485 mitochondria), which may be solved by adding localization signals. Proper localization should be 486 carefully assessed for every bait protein, which is required for any interactome study. 487
As site-directed mutagenesis is accomplished by introduction of a CRISPR/nCas9-cytidine deaminase 488 fusion (BE3), a simple short selection step suffices to obtain a strong enrichment of cells transiently 489 expressing the BE3 base editor and therefore having a high chance of expressing p53-MUTT2A-BirA*. 490
In this way, there is no need to generate separate control cell lines, or to have a design wherein 491 engineered single cell knock in clones are compared to parental populations. Such a design would 492 inevitably lead to higher background levels as presented in this work ( Figure S7, table S8 ). Until 493 genome engineering progresses to efficiencies wherein clonal screening is no longer needed, T2A 494 mutagenesis may be a valuable approach to obtain appropriate isogenic control cell lines. While the 495 devised T2A system allows rigorous control of expression levels, also when gene expression levels are 496 modulated by various stimuli (i.e. doxorubicin effects on p53 levels), the free BirA* cannot replicate 497 the exact localization of the bait protein. A similar localization would allow discrimination between 498 proteins in close proximity and interaction partners (both direct or indirect) [67] . As with all BioID 499 designs, downstream validation is still required to assess this aspect. While we opted for a classic well-500 controlled knock-in approach, novel CRISPR/Cas9 strategies would also allow the selection of isogenic 501 populations (e.g. CRISPR co-selection [68], CRISPaint [69]). 502 503 CONCLUSIONS 504 Taken together, our elegant base editing approach to derive isogenic experimental cell lines from a 505 control cell line enables BioID experiments at the endogenous level. Bringing together the advantages 506 of proximal biotinylation in intact cells with endogenous bait expression levels and with quantitative 507 proteomics pushes protein complex analysis to the next level and constitutes a useful addition to study 508 hub proteins such as p53. 509
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